Premium
Nonalcoholic fatty liver disease and risk of prostatic diseases: Roles of insulin resistance
Author(s) -
Zhao Shankun,
Wang Yaoyao,
Wu Weizhou,
Yang Suqing,
Feng Lili,
Tao Fangfang,
Ge Weiwei,
Shen Maolei,
Xu Weifang
Publication year - 2021
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.14060
Subject(s) - nonalcoholic fatty liver disease , medicine , insulin resistance , metabolic syndrome , prostate cancer , hyperplasia , disease , prostate , diabetes mellitus , fatty liver , lower urinary tract symptoms , cancer , gastroenterology , bioinformatics , insulin , obesity , endocrinology , biology
Nonalcoholic fatty liver disease (NAFLD), the liver component of metabolic syndrome, is considered to be associated with high risk of prostatic diseases but a systematic review has not been conducted. Under a comprehensive review of the eligible clinical studies, a potential positive association between NAFLD and benign prostatic hyperplasia/prostate cancer (BPH/PCa) has been postulated. Insulin resistance and metabolic aberrations are considered to be the potential mechanism for such association. However, the relationship between NAFLD and other prostatic diseases, that is, prostatic inflammation and lower urinary tract symptoms, seems vague due to limited relevant studies in the literatures. The present review highlights that clinicians should be conscious of the detrimental effect of NAFLD on the development of BPH and PCa.